Gastroenterology

Expert Perspectives: Refining
the HBV Treatment Paradigm

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Expert Perspectives: Refining the HBV Treatment Paradigm

View Webcast - requires Flash & high-speed Internet (Tech. Requirements)
View/Download Slides
View/Download Syllabus
Certificate Program Course List

Dear Colleague,

Management of hepatitis B virus (HBV) infection is in an era rich with the potential for significantly improved therapeutic response. In the past 14 months, two additional drugs have been approved for the treatment of HBV: entecavir and peginterferon alfa-2a. Other drugs—such as clevudine, pradefovir, telbivudine, and tenofovir—are advancing in clinical trials. Issues of drug resistance, including the potential benefit of combination therapy, have been further studied and elucidated. Dialogue among experts is continuing, with key outcomes of this dialogue emerging from the recent conference at the National Institutes of Health and international meetings in Vienna and Shanghai, as well as in upcoming updated published position statements.

In the midst of these advances, however, our focus as practicing physicians is steady on the basic building blocks of managing HBV: deciding when to start therapy, choosing an initial therapy, knowing when to switch therapy and what to use next, and identifying the time to stop therapy. These are the issues that matter on a daily basis as we care for our patients infected with HBV.

Our expert faculty of Expert Perspectives: Refining the HBV Treatment Paradigm understand what is important to the practicing physician. Together we'll help you integrate the latest scientific advances into your current management strategies. We'll clarify what the latest research findings and expert opinions mean in terms of starting therapy, choosing an anti-HBV agent, switching agents, and stopping therapy. You'll leave equipped to make good use of the therapeutic advances this current era has to offer.

Thank you for joining us!

Sincerely,

CHAIR
Eugene R. Schiff, MD Leonard Miller Professor of Medicine Chief, Division of Hepatology Director, Center for Liver Diseases University of Miami School of Medicine Miami, Florida

FACULTY
Robert G. Gish, MD Medical Director Liver Transplant Program California Pacific Medical Center San Francisco, California	Ching-Lung Lai, MD Professor of Medicine and Hepatology Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong, China
Kris V. Kowdley, MD Professor of Medicine Division of Gastroenterology/Hepatology University of Washington Medical Center Seattle, Washington	Norah A. Terrault, MD Assistant Professor of Medicine Department of Gastroenterology University of California, San Francisco San Francisco, California

top

TARGET AUDIENCE

This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, and other clinicians who care for patients with hepatitis B infection and patients who are at increased risk for acquiring the infection

ACTIVITY GOAL

The goal of this CME/CE activity is to examine current and emerging strategies for treating patients diagnosed with hepatitis B infection.

LEARNING OBJECTIVES

Formulate HBV treatment strategies, considering safety, efficacy, endpoints, and resistance patterns of currently available and emerging antiviral agents, to improve response rates in patients with HBV infection.
Identify HBV resistance/cross-resistance patterns inherent in approved agents and adjust treatment regimens accordingly to produce optimal outcomes in HBV-infected patients.
Integrate prescribing and monitoring strategies to help prevent or reduce the emergence of resistance into individualized anti-HBV treatment plans for infected patients.
Design treatment plans incorporating knowledge of patient selection, available agents, timing of therapy, monitoring of response, and current expert commentary on HBV management.

top

CME INFORMATION—PHYSICIANS

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CME INFORMATION—PHYSICIAN ASSISTANTS
Projects In Knowledge will issue a certificate of participation for each course the participant completes. Please check with your organization and/or society for reciprocity.

CE INFORMATION—NURSES
This activity has been approved by the American Association of Critical-Care Nurses (AACN) for a maximum of 1.5 contact hours. Provider #00012705.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Updated Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Robert G. Gish, MD, has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, Idun Pharmaceuticals, Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and XTL Biopharmaceuticals; is a consultant for Amgen Inc, Anadys Pharmaceuticals, Inc, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, Innogenetics, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Nucleonics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals International, XTL Biopharmaceuticals, and ZymoGenetics, Inc; and is on the speakers bureau of Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, InterMune Inc, Ortho Biotech Products LP, Schering-Plough Corporation, and Valeant Pharmaceuticals International. Dr. Gish has disclosed that he will reference unlabeled and unapproved uses of adefovir, entecavir, interferon, tenofovir, and tenofovir plus emtricitabine.

Kris V. Kowdley, MD, is on the speakers bureau of Gilead Sciences, Inc, and Hoffmann-La Roche Inc; and is a consultant for Bristol-Myers Squibb and Gilead Sciences, Inc. Dr. Kowdley will not reference unlabeled and unapproved uses of drugs or devices.

Ching-Lung Lai, MD, is a member of advisory boards for Bristol-Myers Squibb and Idenix Pharmaceuticals Inc; and has received honoraria from Bristol-Myers Squibb, Idenix Pharmaceuticals Inc, and LG Life Sciences, Ltd. Dr. Lai will not reference unlabeled and unapproved use of drugs or devices.

Eugene R. Schiff, MD, has received grant/research support from Abbott Laboratories, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Coley Pharmaceutical Group, Gilead Sciences, Inc, GlaxoSmithKline, Idenix Pharmaceuticals Inc, Ortho-Biotech Products, LP, Prometheus Laboratories Inc, Roche Diagnostics, Roche Molecular, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Incorporated; is a consultant for Abbott Laboratories, Achillion Pharmaceuticals, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Cadence Pharmaceuticals, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals Inc, Maxim Pharmaceuticals, National Genetics Institute, Inc, Novartis Pharmaceuticals Corporation, Ortho-Biotech Products, LP, Pfizer Inc, PowerMed Limited, Prometheus Laboratories, Roche Molecular, Sankyo Pharma, Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; and is on the speakers bureau of Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Idenix Pharmaceuticals Inc, Ortho-Biotech Products, LP, and Schering-Plough Corporation. Dr. Schiff has disclosed that he will reference unlabeled and unapproved uses of clevudine and telbivudine.

Norah A. Terrault, MD, has received grant/research support from Cangene Corporation, Gilead Sciences, Inc, Roche Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Bayer Diagnostics and Innogenetics; and is on the speakers bureau of Schering-Plough Corporation. Dr. Terrault has disclosed that she will reference unlabeled and unapproved uses of peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CE activity is supported by an educational grant from
Bristol-Myers Squibb Company.

top

1752